{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:17:17Z","timestamp":1782436637414,"version":"3.54.5"},"reference-count":27,"publisher":"The Endocrine Society","issue":"3","funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>A somatostatin-dopamine chimera (BIM23B065) was under investigation to reduce GH secretion for the treatment of pituitary adenomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine pharmacokinetics, safety, and tolerability and to monitor hormonal changes after single and multiple subcutaneous BIM23B065 administrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Randomized, double-blind, placebo-controlled, parallel-group design with five single and three 13-day multiple ascending-dose cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients<\/jats:title>\n                  <jats:p>A total of 63 healthy male white volunteers were enrolled (47 active, 16 placebo).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Pharmacokinetics, GH, prolactin (PRL), IGF-1, GH after GHRH administration, and general clinical safety criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The maximum dosage of BIM23B065 administered in this study was 1.5 mg. BIM23B065 reduced the mean GH concentrations after 8 and 13 days of treatment. A decrease in GH release after GHRH administration indicated inhibition of the hypothalamic-pituitary-somatotropic axis. IGF-1 was not altered after single doses but showed a significant change from baseline after multiple dosing. PRL secretion was reduced in all subjects who were treated. Orthostatic hypotension and injection site reactions were commonly observed at high dosages. A 6-day uptitration period was included to successfully lower the cardiovascular effects in the multiple ascending dose part of the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Proof of pharmacology of BIM23B065 was shown by a reduction in GH, IGF-1, and PRL concentrations in healthy male volunteers, supporting activity of the somatostatin analog and dopamine agonist moieties. The safety and tolerability of the higher dosing regions was limited mainly by orthostatic hypotension.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2018-01364","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T18:00:40Z","timestamp":1540576840000},"page":"883-891","source":"Crossref","is-referenced-by-count":13,"title":["A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial"],"prefix":"10.1210","volume":"104","author":[{"given":"Wadim M I","family":"de Boon","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-0273","authenticated-orcid":false,"given":"Michiel J","family":"van Esdonk","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, Netherlands"},{"name":"Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0013-8355","authenticated-orcid":false,"given":"Frederik E","family":"Stuurman","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, Netherlands"},{"name":"Leiden University Medical Center, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5817-3594","authenticated-orcid":false,"given":"Nienke R","family":"Biermasz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Leiden University Medical Center, 2333 ZA Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Pons","sequence":"additional","affiliation":[{"name":"Ipsen Innovation, Les Ulis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Paty","sequence":"additional","affiliation":[{"name":"Ipsen Innovation, Les Ulis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7912-0918","authenticated-orcid":false,"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, Netherlands"},{"name":"Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2018,10,26]]},"reference":[{"issue":"1","key":"2020071622252596600_B1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-016-0778-2","article-title":"Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas","volume":"20","author":"Ben-Shlomo","year":"2017","journal-title":"Pituitary"},{"key":"2020071622252596600_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000079048","article-title":"Somatostatin receptors in pituitary function, diagnosis and therapy","volume":"32","author":"Hofland","year":"2004","journal-title":"Front Horm Res"},{"issue":"3","key":"2020071622252596600_B3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","article-title":"Dopamine D2 receptor gene expression in human adenohypophysial adenomas","volume":"14","author":"Stefaneanu","year":"2001","journal-title":"Endocrine"},{"key":"2020071622252596600_B4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"issue":"1\u20132","key":"2020071622252596600_B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.mce.2010.04.020","article-title":"Pituitary tumours: the sst\/D2 receptors as molecular targets","volume":"326","author":"Hofland","year":"2010","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"2020071622252596600_B6","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1210\/en.2007-0378","article-title":"Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules","volume":"148","author":"Gruszka","year":"2007","journal-title":"Endocrinology"},{"key":"2020071622252596600_B7","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1530\/eje.1.02348","article-title":"Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours","volume":"156","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2020071622252596600_B8","first-page":"310","article-title":"Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly","volume":"88","author":"Valea","year":"2015","journal-title":"Clujul Med"},{"issue":"2","key":"2020071622252596600_B9","first-page":"461","article-title":"A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly","volume":"79","author":"Fl\u00f8gstad","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2020071622252596600_B10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.2004.02082.x","article-title":"Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status","volume":"61","author":"Cozzi","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2020071622252596600_B11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1530\/eje.1.01888","article-title":"Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly","volume":"152","author":"Selvarajah","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2020071622252596600_B12","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1055\/s-0031-1287769","article-title":"Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors","volume":"43","author":"Culler","year":"2011","journal-title":"Horm Metab Res"},{"issue":"11","key":"2020071622252596600_B13","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1210\/jc.2003-030302","article-title":"Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin\/dopaminergic chimeric ligand","volume":"88","author":"Ren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622252596600_B14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/B978-0-12-409547-2.12416-3","volume-title":"Comprehensive Medicinal Chemistry III","author":"Hill","year":"2017"},{"key":"2020071622252596600_B15","author":"Saveanu"},{"key":"2020071622252596600_B16","author":"Halem"},{"issue":"6","key":"2020071622252596600_B17","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"},{"issue":"2","key":"2020071622252596600_B18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0950-351X(87)80069-1","article-title":"Prolactin, growth hormone and thyrotropin-thyroid hormone secretion during stress states in man","volume":"1","author":"Delitala","year":"1987","journal-title":"Baillieres Clin Endocrinol Metab"},{"issue":"4","key":"2020071622252596600_B19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10928-017-9526-0","article-title":"A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds","volume":"44","author":"van Esdonk","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"2020071622252596600_B20","first-page":"1441","article-title":"A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day","volume":"74","author":"Van Cauter","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2020071622252596600_B21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","article-title":"How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review","volume":"21","author":"van Esdonk","year":"2018","journal-title":"Pituitary"},{"issue":"2","key":"2020071622252596600_B22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11102-007-0036-8","article-title":"Serum IGF-I levels in the diagnosis and monitoring of acromegaly","volume":"10","author":"Brooke","year":"2007","journal-title":"Pituitary"},{"issue":"4","key":"2020071622252596600_B23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-63-4-941","article-title":"Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients","volume":"63","author":"Ferrari","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071622252596600_B24","first-page":"83","article-title":"Effect of the dopamine agonist bromocriptine on blood pressure, catecholamines and renin activity in acromegalics at rest, following exercise and during insulin induced hypoglycemia","volume":"216","author":"Nilsson","year":"1978","journal-title":"Acta Endocrinol Suppl (Copenh)"},{"issue":"10","key":"2020071622252596600_B25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archneur.57.10.1461","article-title":"Acute orthostatic hypotension when starting dopamine agonists in Parkinson\u2019s disease","volume":"57","author":"Kujawa","year":"2000","journal-title":"Arch Neurol"},{"issue":"12","key":"2020071622252596600_B26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.7326\/0003-4819-113-12-921","article-title":"Cardiovascular effects of the somatostatin analog octreotide in acromegaly","volume":"113","author":"Chanson","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020071622252596600_B27","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-9461-5","volume-title":"Signaling in the Heart.","author":"Mar\u00edn-Garc\u00eda","year":"2011"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/3\/883\/27687854\/jc.2018-01364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/3\/883\/27687854\/jc.2018-01364.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T10:42:05Z","timestamp":1594982525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/3\/883\/5144615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,26]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-01364","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,10,26]]}}}